LEVOFLOXACIN | N021571 | SANTEN INC
| Trial | Phase | Status | Sponsor | Enrollment | Dates |
|---|---|---|---|---|---|
| Phase 2 | Active | Boston University | 271 | 2022-06-07 → 2027-05 | |
| N/A | Active | Turku University Hospital | 552 | 2017-04-03 → 2029-04-01 | |
| N/A | By Invitation | Turku University Hospital | 147 | 2017-08-09 → 2029-08-30 | |
| Phase 3 | Recruiting | UMC Utrecht | 20,000 | 2016-04-11 → 2028-02 | |
| Phase 4 | Completed | Abbott | 271 | 2003-11 | |
| N/A | Completed | City, University of London | 35,000 | 2003-09 → 2006-05 | |
| Phase 3 | Completed | National Taiwan University Hospital | 560 | 2015-02 → 2020-12 | |
| Phase 4 | Completed | Bayer | 401 | 2002-11 → 2004-04 | |
| Phase 4 | Completed | University of Milan | 40 | 2012-01 → 2012-06 | |
| Phase 2 | Completed | Henry Ford Health System | 308 | 2018-03-14 → 2024-08-30 |
Source: ClinicalTrials.gov. Trials matched by ingredient name.
22 active API suppliers hold Drug Master Files for this ingredient.
Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.
| Date | Submission | Document |
|---|---|---|
| Dec 4, 2014 | SUPPL -6 | View Letter (PDF) |
| Mar 2, 2004 | ORIG -1 | View Letter (PDF) |
Source: Drugs@FDA application documents.
No patent or exclusivity listings for this strength.